Additional Prognostic Value of Tumor Grade Beyond the 21-gene Recurrence Score

Yonsei University Health System (YUHS)

Status: Not yet enrolling

Conditions: Breast Cancer; Tumor Grade

Treatments: Other: Tumor grade (I or II vs. III)

Study type: Observational

Funder types: Other

Identifiers

NCT07093775

3-2025-0107

Details and patient eligibility

About

To evaluated the prognostic significance of tumor grade in patients with node-negative, hormone receptor-positive, and human epidermal growth factor receptor 2-negative breast cancers treated according to RS-guided strategies.

Enrollment: 4,000 estimated patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with hormone receptor-positive, HER2-negative early-stage breast cancer
• Patients treated between January 2011 and December 2023
• Patients with available clinicopathologic data and 21-gene Oncotype DX assay results confirmed through electronic medical records

Exclusion criteria

• Patients with breast cancer under the age of 20
• Patients diagnosed with stage IV breast cancer
• Patients for whom clinicopathologic data cannot be retrieved from electronic medical records